• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection

tetano

Editor, Senior Moderator
Vaccine


. 2025 Jun 12:61:127388.
doi: 10.1016/j.vaccine.2025.127388. Online ahead of print. Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice

Eduard Puente-Massaguer[SUP] 1 [/SUP], Kirill Vasilev[SUP] 1 [/SUP], Florian Krammer[SUP] 2 [/SUP]



Affiliations
Abstract

Current seasonal influenza virus vaccines are inefficient at inducing protective immune responses against drifted seasonal or emerging pandemic influenza viruses. A strategy to elicit more broadly cross-protective immune responses is to target conserved epitopes of the influenza virus, and the neuraminidase (NA) glycoprotein and the stalk domain of the hemagglutinin (HA) have become prime vaccine candidates. Sequential immunization with chimeric HA (cHA) antigens in which the immunodominant HA head domain has been replaced by HA head domains of exotic subtypes is able to re-focus the immune response to the HA stalk. Similarly, vaccination with recombinant NA (rNA) protein induces robust anti-NA responses. In this study, we show that sequential immunization with group 2 chimeric HA (cHA) inactivated split vaccines in combination with rN2 NA protein (rNA-N2-MPP) elicits superior immune responses and protection against a heterologous influenza virus in mice.

Keywords: HA stalk; Influenza A; MPP; N2; NA; Universal vaccine; rNA.

 
Back
Top Bottom